David Johnson

David Johnson has a wealth of experience in the biotechnology and genomics industries. David is currently the Founder and CEO of GigaMune, a company focused on developing technology for targeted gene delivery to treat diseases like cancer and autoimmune disorders. Additionally, they serve as an Angel Investor at El Poblenou LLC, investing in early-stage biotech companies and providing advisory support. David has also worked as an Entrepreneur In Residence at Illumina Ventures, a firm that invests in early-stage companies involved in genomics and precision medicine. Prior to these roles, they were the Founder and CEO of GigaGen, Inc, where they developed transformative antibody drugs using single-cell technologies. David also served as the Chief Operating Officer and SVP of Research and Development at Natera, a molecular diagnostic services company specializing in reproductive genetics. David has a strong research background and previously served as the ENCODE Project Director at Stanford University Medical Center, leading a genomics research group focused on characterizing the function of the human genome.

David Johnson holds a Ph.D. in Genetics from Stanford University, which they obtained between 1999 and 2005. Prior to that, they pursued their undergraduate studies at Duke University, completing their AB degree in Biology from 1994 to 1998. In 2001 and 2002, David was a visiting student at the Tokyo Institute of Technology, where they focused on Genetics. Similarly, in 1997, they briefly studied Biology as a visiting student at Universidad San Francisco de Quito. David furthered their education by obtaining a Graduate Certificate in Applied Statistics from Penn State University from 2008 to 2010. Later, in 2013 and 2014, they pursued a Master of Business Administration (MBA) degree at the University of California, Berkeley's Haas School of Business.